Skip to main content
179 results:
106. Sphingotec to Present Novel Acute Care Biomarkers and Point-of-Care Diagnostic Solutions at Medica 2019  
SphingoTec GmbH (“sphingotec”) today announced that latest advancements in the development of its portfolio of novel biomarkers and diagnostic solutions will be showcased at Medica 2019 in…  
107. Novel Data on sphingotec’s penKid® Kidney Function Assay to be Presented at 32nd ESICM Annual Congress 2019  
SphingoTec GmbH (“sphingotec”) today announced that novel data on its sphingotest® penKid® assay for Proenkephalin, a unique and proprietary biomarker for real-time assessment of kidney function,…  
108. Dipeptidyl Peptidase 3 (DPP3) cause of acute myocardial depression: sphingotec launches first IVD test for DPP3 on Nexus IB10 Point-of-Care platform  
Diagnostics company SphingoTec GmbH (“sphingotec”, Hennigsdorf near Berlin, Germany) today launched IB10 sphingotest® DPP3, the first CE-IVD-marked point-of-care biomarker test able to quantify DPP3…  
109. sphingotec reveals novel results on bioactive adrenomedullin for diagnosis and therapy monitoring of septic shock at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM)  
Diagnostics company SphingoTec GmbH reports novel applications of bio-ADM® (bio-active adrenomedullin), the very first biomarker capable to diagnose the onset of septic shock, allowing physicians…  
110. sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference on Advances in Critical Care Nephrology  
German diagnostics company SphingoTec GmbH (Hennigsdorf) announced that leaders in critical care nephrology have confirmed clinical utility of the company’s glomerular filtration biomarker…  
Search results 101 until 110 of 179